Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Zentalis Pharmaceuticals (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on developing a potentially first-in-class and best-in-class WEE1 inhibitor for ovarian cancer and other tumor types, has announced its participation in two major investor conferences.
The company will participate in:
- The TD Cowen 45th Annual Health Care Conference in Boston, MA, with a fireside discussion scheduled for March 3, 2025, at 11:50 a.m. ET
- The Leerink Global Healthcare Conference in Miami, FL, with a fireside discussion scheduled for March 10, 2025, at 9:20 a.m. ET
Live webcasts and archived recordings of both events will be accessible through the 'Events & Presentations' tab on the Investors & Media section of Zentalis' website.
Details
News Market Reaction – ZNTL
The recorded move for ZNTL in the trading session of this news was -4.72%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that members of the management team will participate in the following upcoming investor conferences:
- TD Cowen 45th Annual Health Care Conference, Boston, MA. Fireside discussion, March 3, 2025, 11:50 a.m. ET.
- Leerink Global Healthcare Conference, Miami, FL. Fireside discussion, March 10, 2025, 9:20 a.m. ET.
Access to a live webcast of the TD Cowen and Leerink events, as well as an archived recording, will be available under the “Events & Presentations” tab on the Investors & Media section of the Company’s website.
About Zentalis Pharmaceuticals
Zentalis® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). Azenosertib is being evaluated as a monotherapy and in combination across multiple tumor types in clinical trials and has broad franchise potential. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. The Company is also leveraging its extensive experience and capabilities to translate its science to advance research on additional areas of opportunity for azenosertib outside PROC. Zentalis has operations in San Diego.
For more information, please visit www.zentalis.com. Follow Zentalis on X/Twitter at @ZentalisP and on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals.
Contact:
Haibo Wang - Chief Business Officer
Ron Moldaver - Investor Relations
ir@zentalis.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.